Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
- HDP-101 is well tolerated to date, with no signs of dose-limiting toxicities
- Complete remission observed in one patient from Cohort 5
- Proprietary novel payload with a unique mode of action, representing new treatment options for patients with relapsed or refractory multiple myeloma
Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma.